Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disorder worldwide. It comprises a spectrum of conditions that range from steatosis to non-alcoholic steatohepatitis, with progression to cirrhosis and hepatocellular carcinoma. Currently, there is no FDA-approved pharmacological treatment for NAFLD. The pathogenesis of NAFLD involves genetic and environmental/host factors, including those that cause changes in intestinal microbiota and their metabolites. In this review, we discuss recent findings on the relationship(s) of microbiota signature with severity of NAFLD and the role(s) microbial metabolites in NAFLD progression. We discuss how metabolites may affect NAFLD progression and their potential to serve as biomarkers for NAFLD diagnosis or therapeutic targets for disease management.

Keywords

Non-alcoholic fatty liver disease / gut microbiome / gut microbiota metabolites

References

[1] Younossi Z,Marietti M.Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention..Nat Rev Gastroenterol Hepatol2018;15:11-20

[2] European Association for the Study of the L, European Association for the Study of D, European Association for the Study of OEASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease..J Hepatol2016;64:1388-402

[3] Eslam M,George J.MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease..Gastroenterology2020;158:1999-2014 e1

[4] Eslam M,Sarin SK.A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement..J Hepatol2020;73:202-9

[5] Eslam M,Wong VW.The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease..Hepatol Int2020;

[6] Tilg H.Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis..Hepatology2010;52:1836-46

[7] Sender R,Milo R.Are We Really Vastly Outnumbered? Revisiting the Ratio of Bacterial to Host Cells in Humans..Cell2016;164:337-40

[8] De Filippis F,Vannini L.High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome..Gut2016;65:1812-21

[9] Yatsunenko T,Manary MJ.Human gut microbiome viewed across age and geography..Nature2012;486:222-7 PMCID:PMC3376388

[10] Backhed F,Wang T.The gut microbiota as an environmental factor that regulates fat storage..Proc Natl Acad Sci U S A2004;101:15718-23 PMCID:PMC524219

[11] Backhed F,Semenkovich CF.Mechanisms underlying the resistance to diet-induced obesity in germ-free mice..Proc Natl Acad Sci U S A2007;104:979-84 PMCID:PMC1764762

[12] Daniel H,Berry D.High-fat diet alters gut microbiota physiology in mice..ISME J2014;8:295-308 PMCID:PMC3906816

[13] Le Roy T,Lepage P.Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice..Gut2013;62:1787-94

[14] Wang R,Yang X.Genetically Obese Human Gut Microbiota Induces Liver Steatosis in Germ-Free Mice Fed on Normal Diet..Front Microbiol2018;9:1602 PMCID:PMC6062601

[15] Soderborg TK,Mulligan CE.The gut microbiota in infants of obese mothers increases inflammation and susceptibility to NAFLD..Nat Commun2018;9:4462 PMCID:PMC6203757

[16] Tsai MC,Lin CC.Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan..Nutrients2020;12: PMCID:PMC7146257

[17] Hoyles L,Federici M.Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women..Nat Med2018;24:1070-80 PMCID:PMC6140997

[18] Shen F,Sun XQ,Wang XY.Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease..Hepatobiliary Pancreat Dis Int2017;16:375-81

[19] Raman M,Gillevet PM.Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease..Clin Gastroenterol Hepatol2013;11:868-75 e1-3

[20] Loomba R,Li W.Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease..Cell Metab2017;25:1054-62 e5 PMCID:PMC5502730

[21] Zhu L,Gill C.Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH..Hepatology2013;57:601-9

[22] Wang B,Cao M.Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease..Sci Rep2016;6:32002 PMCID:PMC4994089

[23] Del Chierico F,Vernocchi P.Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach..Hepatology2017;65:451-64

[24] Wong VW,Lam TT.Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis--a longitudinal study..PLoS One2013;8:e62885 PMCID:PMC3636208

[25] Boursier J,Barret M.The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota..Hepatology2016;63:764-75 PMCID:PMC4975935

[26] Schwimmer JB,Angeles JE.Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease..Gastroenterology2019;157:1109-22 PMCID:PMC6756995

[27] Caussy C,Humphrey G.A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease..Nat Commun2019;10:1406 PMCID:PMC6440960

[28] Qin N,Li A.Alterations of the human gut microbiome in liver cirrhosis..Nature2014;513:59-64

[29] Mouzaki M,Arendt BM.Intestinal microbiota in patients with nonalcoholic fatty liver disease..Hepatology2013;58:120-7

[30] Michail S,Frey MR.Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease..FEMS Microbiol Ecol2015;91:1-9 PMCID:PMC4358749

[31] Da Silva HE,Comelli EM.Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance..Sci Rep2018;8:1466 PMCID:PMC5780381

[32] Aron-Wisnewsky J,Witjes J.Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders..Nat Rev Gastroenterol Hepatol2020;17:279-97

[33] Bures J,Kohoutova D.Small intestinal bacterial overgrowth syndrome..World J Gastroenterol2010;16:2978-90 PMCID:PMC2890937

[34] Wigg AJ,Dymock RB,Grose RH.The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis..Gut2001;48:206-11 PMCID:PMC1728215

[35] Miele L,La Torre G.Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease..Hepatology2009;49:1877-87

[36] Rafiei R,Rafiei F.Liver disease symptoms in non-alcoholic fatty liver disease and small intestinal bacterial overgrowth..Rom J Intern Med2018;56:85-9

[37] Saad RJ.Breath testing for small intestinal bacterial overgrowth: maximizing test accuracy..Clin Gastroenterol Hepatol2014;12:1964-72quiz e119-20

[38] Ghoshal UC,Ghoshal U.Low-grade small intestinal bacterial overgrowth is common in patients with non-alcoholic steatohepatitis on quantitative jejunal aspirate culture..Indian J Gastroenterol2017;36:390-9

[39] Fei N,Zhang X.Endotoxin Producers Overgrowing in Human Gut Microbiota as the Causative Agents for Nonalcoholic Fatty Liver Disease..mBio2020;11: PMCID:PMC7002352

[40] Volynets V,Strahl S.Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD)..Dig Dis Sci2012;57:1932-41

[41] Giorgio V,Principessa L.Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity..Dig Liver Dis2014;46:556-60

[42] Luther J,Khalili H.Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability..Cell Mol Gastroenterol Hepatol2015;1:222-32 PMCID:PMC4578658

[43] Mouries J,Silvestri A.Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development..J Hepatol2019;71:1216-28 PMCID:PMC6880766

[44] Nighot M,Guo S.Lipopolysaccharide-Induced Increase in Intestinal Epithelial Tight Permeability Is Mediated by Toll-Like Receptor 4/Myeloid Differentiation Primary Response 88 (MyD88) Activation of Myosin Light Chain Kinase Expression..Am J Pathol2017;187:2698-710 PMCID:PMC5718096

[45] Guo S,Al-Sadi R,Nighot P.Lipopolysaccharide Regulation of Intestinal Tight Junction Permeability Is Mediated by TLR4 Signal Transduction Pathway Activation of FAK and MyD88..J Immunol2015;195:4999-5010 PMCID:PMC4637237

[46] Pappo I,Berry EM.Polymyxin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in the rat..J Surg Res1991;51:106-12

[47] Pappo I,Berry EM,Gallily R.Polymyxin B reduces total parenteral nutrition-associated hepatic steatosis by its antibacterial activity and by blocking deleterious effects of lipopolysaccharide..JPEN J Parenter Enteral Nutr1992;16:529-32

[48] Sharifnia T,Verriere TG.Hepatic TLR4 signaling in obese NAFLD..Am J Physiol Gastrointest Liver Physiol2015;309:G270-8 PMCID:PMC4537925

[49] Harte AL,Creely SJ.Elevated endotoxin levels in non-alcoholic fatty liver disease..J Inflamm (Lond)2010;7:15 PMCID:PMC2873499

[50] Cani PD,Iglesias MA.Metabolic endotoxemia initiates obesity and insulin resistance..Diabetes2007;56:1761-72

[51] Kudo H,Yata Y,Zhang W.Lipopolysaccharide triggered TNF-alpha-induced hepatocyte apoptosis in a murine non-alcoholic steatohepatitis model..J Hepatol2009;51:168-75

[52] Machado MV.Gut microbiota and nonalcoholic fatty liver disease..Ann Hepatol2012;11:440-9

[53] Abu-Shanab A.The role of the gut microbiota in nonalcoholic fatty liver disease..Nat Rev Gastroenterol Hepatol2010;7:691-701

[54] Feldstein AE,Angulo P.Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis..Gastroenterology2003;125:437-43

[55] Canbay A,Gores GJ.Apoptosis: the nexus of liver injury and fibrosis..Hepatology2004;39:273-8

[56] Zhao P,Chaggan C.An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis..Science2020;367:652-60

[57] Garcia-Martinez I,Chen Y.Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9..J Clin Invest2016;126:859-64 PMCID:PMC4767345

[58] An P,Zhao S.Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis..Nat Commun2020;11:2362 PMCID:PMC7217909

[59] Gomes MT,Pereira Gde S,Splitter G.TLR9 is required for MAPK/NF-kappaB activation but does not cooperate with TLR2 or TLR6 to induce host resistance to Brucella abortus..J Leukoc Biol2016;99:771-80 PMCID:PMC6011818

[60] Kawasaki A,Otsuka Y.Synthesis of diaminopimelic acid containing peptidoglycan fragments and tracheal cytotoxin (TCT) and investigation of their biological functions..Chemistry2008;14:10318-30

[61] Yuan L.Bile acid receptors and nonalcoholic fatty liver disease..World J Hepatol2015;7:2811-8 PMCID:PMC4670952

[62] Ridlon JM,Hylemon PB.Bile salt biotransformations by human intestinal bacteria..J Lipid Res2006;47:241-59

[63] Dawson PA.Intestinal transport and metabolism of bile acids..J Lipid Res2015;56:1085-99 PMCID:PMC4442867

[64] Ferslew BC,Johnston CK.Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis..Dig Dis Sci2015;60:3318-28 PMCID:PMC4864493

[65] Kalhan SC,Edmison J.Plasma metabolomic profile in nonalcoholic fatty liver disease..Metabolism2011;60:404-13 PMCID:PMC2950914

[66] Mouzaki M,Bandsma R.Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease..PLoS One2016;11:e0151829 PMCID:PMC4874546

[67] Appleby RN,Khan S.Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study..PLoS One2019;14:e0211348 PMCID:PMC6347262

[68] Yara S IT,Murakami M.Circulating bile acid profiles in Japanese patients with NASH..GastroHep2019;1:302-10

[69] Chen J,Liu J.Ratio of Conjugated Chenodeoxycholic to Muricholic Acids is Associated with Severity of Nonalcoholic Steatohepatitis..Obesity (Silver Spring)2019;27:2055-66

[70] Pols TW,Nomura M,Schoonjans K.The bile acid membrane receptor TGR5: a valuable metabolic target..Dig Dis2011;29:37-44 PMCID:PMC3128138

[71] Fiorucci S,Zampella A.Bile Acids Activated Receptors Regulate Innate Immunity..Front Immunol2018;9:1853 PMCID:PMC6099188

[72] Molinaro A,Marschall HU.Role of Bile Acids in Metabolic Control..Trends Endocrinol Metab2018;29:31-41

[73] Kawamata Y,Hosoya M.A G protein-coupled receptor responsive to bile acids..J Biol Chem2003;278:9435-40

[74] Thomas C,Noriega L.TGR5-mediated bile acid sensing controls glucose homeostasis..Cell Metab2009;10:167-77 PMCID:PMC2739652

[75] Keitel V,Winandy S,Haussinger D.Expression and function of the bile acid receptor TGR5 in Kupffer cells..Biochem Biophys Res Commun2008;372:78-84

[76] Higuchi H,Takikawa Y.The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis..J Biol Chem2001;276:38610-8

[77] Higuchi H,Canbay A,Gores GJ.Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1..J Biol Chem2004;279:51-60

[78] Faubion WA,Miyoshi H.Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas..J Clin Invest1999;103:137-45 PMCID:PMC407865

[79] Qiao L,Leach K.Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis..Mol Biol Cell2001;12:2629-45 PMCID:PMC59700

[80] Ibrahim S,Krautbauer S.Bile acid-induced apoptosis and bile acid synthesis are reduced by over-expression of Augmenter of Liver Regeneration (ALR) in a STAT3-dependent mechanism..Exp Cell Res2019;374:189-97

[81] Schaap FG,Jansen PL.Bile acid receptors as targets for drug development..Nat Rev Gastroenterol Hepatol2014;11:55-67

[82] Claudel T,Kuipers F.The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism..Arterioscler Thromb Vasc Biol2005;25:2020-30

[83] Mudaliar S,Sanyal AJ.Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease..Gastroenterology2013;145:574-82 e1

[84] Neuschwander-Tetri BA,Sanyal AJ.Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial..Lancet2015;385:956-65 PMCID:PMC4447192

[85] Younossi ZM,Loomba R.Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial..Lancet2019;394:2184-96

[86] Siddiqui MS,Connelly MA.Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis..J Hepatol2020;72:25-33 PMCID:PMC6920569

[87] Pencek R,Roth JD,Hooshmand-Rad R.Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers..Diabetes Obes Metab2016;18:936-40

[88] Pockros PJ,Freilich B.CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients..Liver Int2019;39:2082-93

[89] Patel K,Elkhashab M.Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial..Hepatology2020;72:58-71

[90] Pedrosa M,Francque S.A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial..Contemp Clin Trials2020;88:105889

[91] Friedman ES,Shen TD.FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid..Gastroenterology2018;155:1741-52 e5 PMCID:PMC6279623

[92] Yajima M,Tsuruta T.Diversity of the intestinal microbiota differently affects non-neuronal and atropine-sensitive ileal contractile responses to short-chain fatty acids in mice..Biomed Res2016;37:319-28

[93] Wolever TM,Royall D,Jenkins DJ.Effect of rectal infusion of short chain fatty acids in human subjects..Am J Gastroenterol1989;84:1027-33

[94] McNeil NI.The contribution of the large intestine to energy supplies in man..Am J Clin Nutr1984;39:338-42

[95] Samuel BS,Motoike T.Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41..Proc Natl Acad Sci U S A2008;105:16767-72 PMCID:PMC2569967

[96] Musso G,Cassader M.Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded?.Diabetes Care2010;33:2277-84 PMCID:PMC2945175

[97] Svegliati-Baroni G,Rychlicki C.Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis..Liver Int2011;31:1285-97

[98] Tolhurst G,Lam YS.Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2..Diabetes2012;61:364-71 PMCID:PMC3266401

[99] Ge H,Weiszmann J.Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids..Endocrinology2008;149:4519-26

[100] Zhao S,Liu J.Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate..Nature2020;579:586-91 PMCID:PMC7416516

[101] Hanson RW.The relative significance of acetate and glucose as precursors for lipid synthesis in liver and adipose tissue from ruminants..Biochem J1967;105:529-36 PMCID:PMC1198341

[102] den Besten G,Havinga R.Gut-derived short-chain fatty acids are vividly assimilated into host carbohydrates and lipids..Am J Physiol Gastrointest Liver Physiol2013;305:G900-10

[103] Weidemann MJ,Williams DL,Krebs HA.Gluconeogenesis from propionate in kidney and liver of the vitamin B12-deficient rat..Biochem J1970;117:177-81 PMCID:PMC1178844

[104] Iannucci LF,Singh BK.Short chain fatty acids induce UCP2-mediated autophagy in hepatic cells..Biochem Biophys Res Commun2016;480:461-7

[105] Singh R,Wang Y.Autophagy regulates lipid metabolism..Nature2009;458:1131-5 PMCID:PMC2676208

[106] Sinha RA,Zhou J.Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy..J Clin Invest2012;122:2428-38 PMCID:PMC3386813

[107] Gao Z,Zhang J.Butyrate improves insulin sensitivity and increases energy expenditure in mice..Diabetes2009;58:1509-17 PMCID:PMC2699871

[108] den Besten G,Gerding A.Short-Chain Fatty Acids Protect Against High-Fat Diet-Induced Obesity via a PPARgamma-Dependent Switch From Lipogenesis to Fat Oxidation..Diabetes2015;64:2398-408

[109] Waldecker M,Daumann H,Schrenk D.Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon..J Nutr Biochem2008;19:587-93

[110] Juanola O,Garcia-Villalba R.Circulating levels of butyrate are inversely related to portal hypertension, endotoxemia, and systemic inflammation in patients with cirrhosis..FASEB J2019;33:11595-605

[111] Zhai S,Li L,Zou Z.Dietary butyrate suppresses inflammation through modulating gut microbiota in high-fat diet-fed mice..FEMS Microbiol Lett2019;366:

[112] Sun B,Hong J.Sodium Butyrate Ameliorates High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease through Peroxisome Proliferator-Activated Receptor alpha-Mediated Activation of beta Oxidation and Suppression of Inflammation..J Agric Food Chem2018;66:7633-42

[113] Baumann A,Brandt A.Oral Supplementation of Sodium Butyrate Attenuates the Progression of Non-Alcoholic Steatohepatitis..Nutrients2020;12: PMCID:PMC7231312

[114] Cope K,Diehl AM.Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis..Gastroenterology2000;119:1340-7

[115] Dawes EA.The formation of ethanol in Escherichia coli..Biochim Biophys Acta1956;22:253-65

[116] Nair S,Risby TH.Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis..Am J Gastroenterol2001;96:1200-4

[117] Baker SS,Liu W,Zhu L.Role of alcohol metabolism in non-alcoholic steatohepatitis..PLoS One2010;5:e9570 PMCID:PMC2833196

[118] Engstler AJ,Degen C.Insulin resistance alters hepatic ethanol metabolism: studies in mice and children with non-alcoholic fatty liver disease..Gut2016;65:1564-71

[119] Gaitantzi H,Rakoczy P.Ethanol sensitizes hepatocytes for TGF-beta-triggered apoptosis..Cell Death Dis2018;9:51 PMCID:PMC5833779

[120] Parlesak A,Schutz T,Bode C.Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease..J Hepatol2000;32:742-7

[121] Wang Z,Bennett BJ.Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease..Nature2011;472:57-63 PMCID:PMC3086762

[122] Mehedint MG.Choline’s role in maintaining liver function: new evidence for epigenetic mechanisms..Curr Opin Clin Nutr Metab Care2013;16:339-45 PMCID:PMC3729018

[123] Yao ZM.Reduction in VLDL, but not HDL, in plasma of rats deficient in choline..Biochem Cell Biol1990;68:552-8

[124] Stephenson K,Hargrove L.Updates on Dietary Models of Nonalcoholic Fatty Liver Disease: Current Studies and Insights..Gene Expr2018;18:5-17 PMCID:PMC5860971

[125] Dumas ME,Toye A.Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice..Proc Natl Acad Sci U S A2006;103:12511-6 PMCID:PMC1567909

[126] Koeth RA,Levison BS.Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis..Nat Med2013;19:576-85 PMCID:PMC3650111

[127] Chen YM,Zhou RF.Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults..Sci Rep2016;6:19076 PMCID:PMC4705470

[128] Leon-Mimila P,Li XS.Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes..Diabetes Metab2020;

[129] Barrea L,Muscogiuri G.Trimethylamine-N-oxide (TMAO) as Novel Potential Biomarker of Early Predictors of Metabolic Syndrome..Nutrients2018;10: PMCID:PMC6316855

[130] De Chiara F,Habtesion A.Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver Disease..Hepatology2020;71:874-92

[131] De Chiara F,Marrone G.Urea cycle dysregulation in non-alcoholic fatty liver disease..J Hepatol2018;69:905-15

[132] Thomsen KL,Rombouts K.Ammonia: A novel target for the treatment of non-alcoholic steatohepatitis..Med Hypotheses2018;113:91-7

[133] Richardson AJ,Wallace RJ.Ammonia production by human faecal bacteria, and the enumeration, isolation and characterization of bacteria capable of growth on peptides and amino acids..BMC Microbiol2013;13:6 PMCID:PMC3554466

[134] Wiest R,Trauner M,Jalan R.Targeting the gut-liver axis in liver disease..J Hepatol2017;67:1084-103

[135] Jiang C,Li F.Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease..J Clin Invest2015;125:386-402 PMCID:PMC4382255

[136] Wu WC,Li S.Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats..World J Gastroenterol2008;14:313-7 PMCID:PMC2675133

[137] Gangarapu V,Baysal B.Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease..Eur J Gastroenterol Hepatol2015;27:840-5

[138] Paolella G,Pierri L,Di Stasi M.Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease..World J Gastroenterol2014;20:15518-31 PMCID:PMC4229517

[139] Hu H,Kong M.Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives..J Gastroenterol2020;55:142-58 PMCID:PMC6981320

[140] Jayakumar S.Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications..Aliment Pharmacol Ther2019;50:144-58 PMCID:PMC6771496

[141] Perdomo CM,Escalada J.Impact of Nutritional Changes on Nonalcoholic Fatty Liver Disease..Nutrients2019;11: PMCID:PMC6470750

[142] Xiao MW,Shen ZH,Wang XY.Systematic Review with Meta-Analysis: The Effects of Probiotics in Nonalcoholic Fatty Liver Disease..Gastroenterol Res Pract2019;2019:1484598 PMCID:PMC6927028

[143] Ma YY,Yu CH,Chen LH.Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis..World J Gastroenterol2013;19:6911-8 PMCID:PMC3812493

[144] Alisi A,Nobili V.Paediatric nonalcoholic fatty liver disease..Curr Opin Gastroenterol2013;29:279-84

[145] Liu Q,Li F.Probiotic culture supernatant improves metabolic function through FGF21-adiponectin pathway in mice..J Nutr Biochem2020;75:108256

[146] Raso GM,Iacono A.Effects of a Lactobacillus paracasei B21060 based synbiotic on steatosis, insulin signaling and toll-like receptor expression in rats fed a high-fat diet..J Nutr Biochem2014;25:81-90

[147] Malaguarnera G,Vacante M.Probiotics in the gastrointestinal diseases of the elderly..J Nutr Health Aging2012;16:402-10

[148] Asgharian A,Esmailzade A,Mohammadi V.The Effect of Symbiotic Supplementation on Liver Enzymes, C-reactive Protein and Ultrasound Findings in Patients with Non-alcoholic Fatty Liver Disease: A Clinical Trial..Int J Prev Med2016;7:59 PMCID:PMC4809112

[149] Song Y,Girotra M.Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection..PLoS One2013;8:e81330 PMCID:PMC3841263

[150] Kelly CR,Staley C.Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection: A Randomized Trial..Ann Intern Med2016;165:609-16 PMCID:PMC5909820

[151] Zhou D,Shen F.Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota..Sci Rep2017;7:1529 PMCID:PMC5431549

[152] Porras D,Martinez-Florez S,Garcia-Mediavilla MV.Intestinal Microbiota Modulation in Obesity-Related Non-alcoholic Fatty Liver Disease..Front Physiol2018;9:1813 PMCID:PMC6305464

[153] Vrieze A,Holleman F.Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome..Gastroenterology2012;143:913-6 e7

[154] Garcia-Lezana T,Bravo M.Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis..Hepatology2018;67:1485-98

[155] Day CP.Non-alcoholic steatohepatitis: definitions and pathogenesis..J Gastroenterol Hepatol.2002;17 Suppl 3:S377-84

[156] Hardy T,Anstee QM.Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum..Annu Rev Pathol2016;11:451-96

[157] Powell EE,Hanson R,Halliday JW.The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years..Hepatology1990;11:74-80

[158] Ascha MS,Lopez R,Feldstein AF.The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis..Hepatology2010;51:1972-8

[159] Sanyal A,Moyneur E.Population-based risk factors and resource utilization for HCC: US perspective..Curr Med Res Opin2010;26:2183-91

[160] Kim GA,Choe J.Association between non-alcoholic fatty liver disease and cancer incidence rate..J Hepatol2017;

[161] Pais R,Goumard C.Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period..Aliment Pharmacol Ther2017;46:856-63

[162] Tsuchida T,Fujiwara N.A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer..J Hepatol2018;69:385-95 PMCID:PMC6054570

[163] Raza S,Anjum B.Molecular links between non-alcoholic fatty liver disease and hepatocellular carcinoma..Hepatoma Res2019;5:42 PMCID:PMC6924993

[164] Hirsova P,Dohnalkova E.Hepatocyte apoptosis is tumor promoting in murine nonalcoholic steatohepatitis..Cell Death Dis2020;11:80 PMCID:PMC6997423

[165] Michelotti GA,Diehl AM.NAFLD, NASH and liver cancer..Nat Rev Gastroenterol Hepatol2013;10:656-65

[166] Cholankeril G,Khurana S.Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management..World J Hepatol2017;9:533-43 PMCID:PMC5395802

[167] Ponziani FR,Castelli C.Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease..Hepatology2019;69:107-20

[168] Chen YH,Wu MS.Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review..Int J Mol Sci2020;21: PMCID:PMC7504062

[169] Dapito DH,Gwak GY.Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4..Cancer Cell2012;21:504-16 PMCID:PMC3332000

[170] Yuan D,Berger E.Kupffer Cell-Derived Tnf Triggers Cholangiocellular Tumorigenesis through JNK due to Chronic Mitochondrial Dysfunction and ROS..Cancer Cell2017;31:771-89 e6

[171] Loo TM,Watanabe Y.Gut Microbiota Promotes Obesity-Associated Liver Cancer through PGE2-Mediated Suppression of Antitumor Immunity..Cancer Discov2017;7:522-38

[172] Wang X,Van Ness C,Ma X.Bile Acid Receptors and Liver Cancer..Curr Pathobiol Rep2013;1:29-35 PMCID:PMC3571718

[173] Chen T,Wang X.Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma..Mol Cell Proteomics2011;10:M110 004945 PMCID:PMC3134066

[174] Jansen PL.Endogenous bile acids as carcinogens..J Hepatol2007;47:434-5

[175] Knisely AS,Meier Y.Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency..Hepatology2006;44:478-86

[176] Ma C,Heinrich B.Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells..Science2018;360: PMCID:PMC6407885

[177] Yamada S,Watanabe M.Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice..Oncotarget2018;9:9925-39 PMCID:PMC5839411